Macrocyclic Peptides, HBOT, & South Korea’s Longevity Boom | Longevity News Roundup — Week 12, 2026

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals. Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.______________________News & References:Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠